Bluefin Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-367,500
Closed -$1K 972
2021
Q4
$1K Hold
367,500
﹤0.01% 909
2021
Q3
$25K Hold
367,500
﹤0.01% 606
2021
Q2
$53K Sell
367,500
-74,500
-17% -$789K ﹤0.01% 507
2021
Q1
$260K Buy
+442,000
New +$5.07M 0.01% 424
2019
Q1
Sell
-160,000
Closed -$1K 488
2018
Q4
$1K Hold
160,000
﹤0.01% 407
2018
Q3
$5K Hold
160,000
﹤0.01% 491
2018
Q2
$5K Hold
160,000
﹤0.01% 402
2018
Q1
$5K Hold
160,000
﹤0.01% 399
2017
Q4
$6K Hold
160,000
﹤0.01% 436
2017
Q3
$14K Buy
+160,000
New +$3.6M ﹤0.01% 432
2014
Q4
Sell
-15,000
Closed -$2K 893
2014
Q3
$2K Buy
+15,000
New +$795K ﹤0.01% 916

Other funds holding TEVA

Bluefin Capital Management's TEVA Position: Q1 2022 in Review

Bluefin Capital Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2022, closing a stake of 15,237 shares — an estimated $122K sold.

Bluefin Capital Management first reported a position in TEVA in Q3 2014 and held it in 10 quarters. The position peaked at $4.57M in Q2 2015. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

  • Bluefin Capital Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2022 after selling out during the quarter.
  • Bluefin Capital Management sold 15,237 Teva Pharmaceutical Industries Limited shares in Q1 2022, an estimated $122K.
  • Bluefin Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q3 2014 and held it in 10 quarters.
  • Bluefin Capital Management's Teva Pharmaceutical Industries Limited position peaked at $4.57M in Q2 2015.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2022.

Based on Bluefin Capital Management's 13F filing for Q1 2022, filed 16 May 2022.